Dantrolene
A muscle relaxant that acts directly on skeletal muscle by inhibiting calcium release from the sarcoplasmic reticulum, used to treat malignant hyperthermia, neuroleptic malignant syndrome, and chronic spasticity. It is the only drug effective for the life-threatening muscle rigidity of malignant hyperthermia.
Peso Molecular
314,2500 g/mol
LogP
1,70
TPSA
121,00 Ų
Regra dos 5 de Lipinski
Aprovado
Áreas Terapêuticas
Mecanismo de Ação
Reduces skeletal muscle tone and spasm through central or peripheral mechanisms, typically by modulating spinal reflexes, enhancing inhibitory neurotransmission, or blocking neuromuscular transmission.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Reduces skeletal muscle tone and spasm through central or peripheral mechanisms, typically by modulating spinal reflexes, enhancing inhibitory neurotransmission, or blocking neuromuscular transmission.
Estrutura 2D
Cite this structure
Embed this structure
SMILES
O=C1CN(/N=C/c2ccc(-c3ccc([N+](=O)[O-])cc3)o2)C(=O)N1
InChI
InChI=1S/C14H10N4O5/c19-13-8-17(14(20)16-13)15-7-11-5-6-12(23-11)9-1-3-10(4-2-9)18(21)22/h1-7H,8H2,(H,16,19,20)/b15-7+
Molecular Formula
C14H10N4O5
HBD / HBA
1 / 6
Ligações Rotacionáveis
3
Átomos Pesados
23
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Perguntas frequentes
A muscle relaxant that acts directly on skeletal muscle by inhibiting calcium release from the sarcoplasmic reticulum, used to treat malignant hyperthermia, neuroleptic malignant syndrome, and chronic spasticity. It is the only drug effective for the life-threatening muscle rigidity of malignant hyperthermia.
Reduces skeletal muscle tone and spasm through central or peripheral mechanisms, typically by modulating spinal reflexes, enhancing inhibitory neurotransmission, or blocking neuromuscular transmission.
Yes, Dantrolene is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1201288. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 6914273. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="dantrolene"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/dantrolene/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/dantrolene/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/dantrolene/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="dantrolene"></drugfyi-drug>